


In the format provided by the authors and unedited.

Hyperactivated PI3K δ promotes self and commensal reactivity at the expense of optimal humoral immunity

Silvia Preite^{1,2*}, Jennifer L. Cannons^{1,2,12}, Andrea J. Radtke^{2,12}, Ivan Vujkovic-Cvijin^{3,12}, Julio Gomez-Rodriguez^{1,2}, Stefano Volpi^{4,5}, Bonnie Huang^{1,2}, Jun Cheng¹, Nicholas Collins³, Julie Reilley^{1,2}, Robin Handon¹, Kerry Dobbs⁶, Lutfi Huq³, Indu Raman⁷, Chengsong Zhu⁷, Quan-Zhen Li^{7,8}, Ming O. Li⁹, Stefania Pittaluga¹⁰, Gulbu Uzel⁶, Luigi D. Notarangelo⁶, Yasmine Belkaid^{3,11}, Ronald N. Germain² and Pamela L. Schwartzberg^{1,2*}


¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. ²Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ³Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ⁴Clinica Pediatrica e Reumatologia, Centro per le Malattie Autoinfiammatorie e Immunodeficienze, Istituto Giannina Gaslini, Genoa, Italy. ⁵Università degli Studi di Genova, Genoa, Italy. ⁶Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ⁷Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, USA. ⁸Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA. ⁹Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. ¹⁰Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ¹¹Microbiome Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ¹²These authors contributed equally to this work: Jennifer L. Cannons, Andrea J. Radtke, Ivan Vujkovic-Cvijin. *e-mail: silvia.preite@nih.gov; pams@mail.nih.gov



Supplementary Figure 1

Basal characterization of *Pik3cd*^{E1020K/+} mouse model.


a, Schematic representation of *Pik3cd*^{E1020K/+} generation. After crossing to ZP3-Cre mice to remove the neoR cassette, the point mutation and one LoxP site in the upstream intron remain. **(b, d-h)** Wild-type and *Pik3cd*^{E1020K/+} mice were analyzed at steady state between 2 and 4 months of age. **b**, Cellularity of resting lymph node (n=5 per group). **c**, Representative contour plots of CD44 and CD62L on CD4⁺ T cells in the spleen of 1-year-old mice. **d**, Numbers of CD93⁺CD138[−] transitional B cells in the spleen (percent of B220⁺CD19⁺); representative flow staining and histograms of percentages and numbers of T1, T2, T3 and IgM[−]CD23[−] B cells (gated on B220⁺CD19⁺CD93⁺CD138[−]) (wild-type n=3, *Pik3cd*^{E1020K/+} n=4). **e**, Representative FACS plots of surface IgM and IgD (gated on B220⁺CD19⁺ B cells in the spleen) and relative histograms (wild-type n=8 *Pik3cd*^{E1020K/+} n=7). **f**, Illustrative contour plots for CD21 and CD23 to identify MZ, FO, and CD21[−]CD23[−] B cells in the spleen (percent of B220⁺CD19⁺). Bar graph on the right (wild-type n=6, *Pik3cd*^{E1020K/+} n=5). **(g-h)** Analysis of peritoneal cavity (n=3 per group). **g**, Cellularity of peritoneal lavage; representative flow staining and cell counts of CD3⁺ T and CD19⁺ B cells. **h**, Representative contour plots and cell counts of B1 (CD23[−]) and B2 (CD23⁺) B cells gated on CD19⁺ cells as in **(g)**; on the right, representative histograms and numbers of B1a (CD5⁺) and B1b (CD5[−]) gated on B1 B cells. Data in **(b-f)** are representative of three, and data in **(g,h)** of two, independent experiments. Data are represented as mean ± SEM with each dot indicating one mouse. Significance analyzed by Mann-Whitney U test. **P* < 0.05; ***P* < 0.01; ****P* < 0.001.



Supplementary Figure 2

Baseline immune response of wild-type and *Pik3cd*^{E1020K/+} mice in lymph node and spleen.


a, Representative flow plots and histogram of BCL-6 and CXCR5 staining for GC-T_{TH}, pre-T_{TH} and non-T_{TH} cells (gated on CD4⁺B220[−] T cells in the spleen) (n=6 per group). **b**, Frequency of PD-1⁺CXCR5⁺Foxp3[−] T_{TH} cells (percent of CD4⁺B220[−] T cells) in the popliteal lymph node of 2 and 4-month-old mice at steady state. **c**, Representative flow plots and cell counts of CD4⁺ follicular T cells: CXCR5⁺PD-1⁺ (left panel) and CXCR5⁺ICOS⁺ (right panel) in 1-year-old mice in the spleen. **d**, Frequency of GL-7⁺FAS⁺ GC B cells (percent of B220⁺CD19⁺ B cells) in the popliteal lymph node of 2 and 4-month-old mice at steady state (**b,d**, 2 month-old, n=5 per group; 4 month-old, wild-type n=8, *Pik3cd*^{E1020K/+} n=7). **e**, Representative flow plots and cell counts of GL-7⁺FAS⁺ GC B cells (percent of B220⁺CD19⁺ B cells, left panel), IgD⁺ B cells (percent of B220⁺CD19⁺ B cells, right panel), and CD138⁺B220^{int/lo} plasma cells (of live cells, lower panel) in 1-year-old mice in the spleen (**c, e**, wild-type n=3, *Pik3cd*^{E1020K/+} n=5). Data are representative of two independent experiments. Data are represented as mean ± SEM. Significance analyzed by Mann-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001.



Supplementary Figure 3

Immune response to NP-OVA in wild-type and *Pik3cd*^{E1020K/+} mice.

Wild-type and *Pik3cd*^{E1020K/+} mice were immunized subcutaneously, at different age (2-months, 4-months, 1-year-old), with NP-OVA in alum in the hock and sacrificed on day+10. Analyses performed on draining (dLN) and resting (rLN) popliteal lymph nodes. **a**, Analyses of 2-month-old mice: frequency of PD-1⁺CXCR5⁺Foxp3⁻ T_{FH} cells (percent of CD4⁺B220⁻ T cells, left panel) and GL-7⁺FAS⁺ GC B cells (of B220⁺CD19⁺ B cells, right panel) in rLN and dLN (n=5 per group). **(b-c)** Analyses of 4-month-old mice. **b**, cellularity of rLN and dLN (n=6 per group). **c**, Numbers of NP⁻ and NP⁺ GC B cells in dLN (wild-type n=6, *Pik3cd*^{E1020K/+} n=5). **d**, Analyses of 1-year-old mice: percentage and numbers of NP⁺ GC B cells in dLN (wild-type n=7, *Pik3cd*^{E1020K/+} n=9). **e**, Analyses of 2-month-old mice: percentage of NP⁺ GC B cells and ratios between numbers of NP⁺ and NP⁻ GC B cells in dLN (n=5 per group). **f**, Analyses of 4-month-old mice: ELISA for serum IgG1 (wild-type n=8, *Pik3cd*^{E1020K/+} n=6). **(g-m)** Analyses based on Figure 3g. **g**, Proportion of FDC networks with a GC having greater than 10 BCL-6⁺ cells (wild-type rLN, n=3; wild-type dLN, n=2; *Pik3cd*^{E1020K/+} rLN and dLN n=3). Each symbol represents an entire LN section corresponding to 5-8 FDC networks. **h**, Area of BCL-6⁺ GCs per FDC region. Each symbol corresponds to a GC (wild-type rLN, n=3; wild-type dLN, n=5; *Pik3cd*^{E1020K/+} rLN, n=13; *Pik3cd*^{E1020K/+} dLN n=6). **i**, Histo-cytometric representation of GCs from wild-type dLN depicted in Figure 3g, II. The distribution of PD-1⁺CD4⁺ T cells within the LZ and DZ of the GC was determined using the density of CD35 and BCL-6 to mark the LZ and DZ, respectively. **j**, Percentage of T_{FH} cells (PD-1⁺CD4⁺ surfaces) in the DZ as determined by histo-cytometry. **k**, Normalized numbers of T_{FH} cells (identified as in **j**) per DZ GC area (BCL-6⁺CD35⁻). Each symbol corresponds to a GC (**j,k**, wild-type dLN, n=4; *Pik3cd*^{E1020K/+} rLN, n=12; *Pik3cd*^{E1020K/+} dLN n=6). IF analyses are representative of 2-3 independent lymph nodes analyzed. **l**, Representative FACS plots and histograms of DZ (CXCR4^{hi}CD86^{lo}) and LZ (CXCR4^{lo}CD86^{hi}) gated on NP⁺ GC B cells (wild-type n=8, *Pik3cd*^{E1020K/+} n=7). **m**, Percentage (of live cells) and numbers of CD4⁺B220⁻CXCR5⁻PD1⁻Foxp3⁺ T_{reg} cells, and CD4⁺B220⁻PD-1⁺CXCR5⁺Foxp3⁺ T_{FR} cells in rLN and dLN (wild-type n=8, *Pik3cd*^{E1020K/+} n=7). Data in **(a-f, l, m)** are representative of two independent experiments. Shown is the mean ± SEM. Significance analyzed by Mann-Whitney U test. **P* < 0.05; ***P* < 0.01; ****P* < 0.001.




Supplementary Figure 4

T cell intrinsic roles of hyperactivated PI3K δ .

(a-b, c, j) Experimental setting described in Figure 4a. a, Representative CD44 histogram on wild-type and *Pik3cd*^{E1020K/+} OT-II cells


and endogenous CD4⁺ T cells. **b**, Representative flow plots and histograms of GC-T_{FH}, pre-T_{FH} and non-T_{FH} cells (gated on transferred OT-II cells in the spleen) (wild-type n=7, *Pik3cd*^{E1020K/+} n=6). **c**, Intracellular staining for IL-21 after *in vitro* re-stimulation with PMA/Ionomycin on FACS sorted wild-type or *Pik3cd*^{E1020K/+} OT-II non-T_{FH} cells (PD1⁻CXCR5⁻CD4⁺B220⁻) and T_{FH} cells (PD1⁺CXCR5⁺CD4⁺B220⁻), isolated on day +7 post immunization, as described in Fig. 4a (pool of wild-type OT-II (n=7) and *Pik3cd*^{E1020K/+} OT-II cells (n=6)). **d**, Analysis of IgG supernatant on *in vitro* culture between wild-type B cells and wild-type or *Pik3cd*^{E1020K/+} polyclonal T_{FH} cells stimulated with anti-IgM and anti-CD3 for 7 days (pool of 4-5 mice per group). **e**, Frequency of endogenous PD-1⁺CXCR5⁺ of CD4⁺ B220⁻ T cells in wild-type mice adoptively transferred with wild-type or *Pik3cd*^{E1020K/+} OT-II cells and treated with isotype control (wild-type OT-II n=5, *Pik3cd*^{E1020K/+} OT-II n=4), or anti-ICOS-L (wild-type OT-II n=4, *Pik3cd*^{E1020K/+} OT-II n=5) (experiment described in Fig. 4d). **f**, Experiment outline of (**g**, **h**). Naïve wild-type and *Pik3cd*^{E1020K/+} mice received isotype control (wild-type n=5, *Pik3cd*^{E1020K/+} n=5), or anti-ICOS-L (wild-type n=6, *Pik3cd*^{E1020K/+} n=5) on day 0 (i.v.), +2, +4, +6 (i.p.) and were sacrificed on day+7 post treatment. **g**, Representative contour plots and histogram of endogenous PD-1⁺CXCR5⁺ T cells (of CD4⁺B220⁻). **h**, Histogram of FAS⁺GL-7⁺ GC B cells (of B220⁺CD19⁺ B cells). **i**, Analysis of CD69 and CD25 on wild-type and *Pik3cd*^{E1020K/+} naïve OT-II cells activated *in vitro* with CD11c⁺ DC and OVA₃₂₃₋₃₃₉ for 20 h (pool of 2-3 mice per group). **j**, Frequency of FAS⁺GL-7⁺ GC B cells (of B220⁺CD19⁺ B cells) related to Fig. 4a (wild-type n=7, *Pik3cd*^{E1020K/+} n=6). Data are representative of two independent experiments. Data are expressed as mean ± SEM with each dot indicating one mouse. Significance analyzed by Mann-Whitney U test. **P* < 0.05; ***P* < 0.01.




Supplementary Figure 5

B cell intrinsic roles of hyperactivated PI3K δ .

a, Related to Figure 5a. Frequency of wild-type OT-II and wild-type OT-II T_{FH} cells (PD-1⁺CXCR5⁺CD4⁺B220⁻) in wild-type hosts together with wild-type (n=8) or mutant (n=7) MD4 B cells immunized i.p. with HEL-OVA₃₂₃₋₃₃₉ in alum. **b**, Schematic experimental layout for panels (**c-f**). Wild-type OT-II (CD45.1⁺) and wild-type (n=6) or *Pik3cd*^{E1020K/+} (n=8) polyclonal B cells (CD45.2⁺) were adoptively transferred into MD4 hosts (CD45.1/2⁺) and immunized i.p. with NP-OVA in alum. Analysis in the spleen on day+8. **c**, Frequency of transferred polyclonal CD45.2⁺B220⁺CD19⁺ B cells (of live cells). **d**, Numbers of transferred CD45.2⁺B220⁺CD19⁺GL-7⁺FAS⁺ GC B cells. **e**, Frequency of polyclonal CD138⁺B220^{int/lo} plasma cells/blasts (of transferred CD45.2⁺ cells). **f**, Representative contour plots of frequency of NP⁺ GC B cells within transferred B cells, histogram of NP⁺ GC B cells, and ratio between numbers of NP⁺ and NP⁻ GC B cells. **g**, Analysis of CD86 and CD69 on wild-type and *Pik3cd*^{E1020K/+} follicular (FO) MD4 B cells activated *in vitro* with HEL for 20 h (pool of 2-3 mice per group). **h**, Analysis of *in vitro* differentiated plasma cells (BLIMP-1-YFP⁺CD138⁺) generated from FO B cells stimulated with LPS and IL-4 or IL-21 for 3 days (gated on live B cells) (pool of 2-3 mice per group). **i**, Experimental outline of mixed BM chimeras between different ratios (20:80 n=6, 80:20 n=10, 50:50 n=2) of wild-type (CD45.1⁺) and *Pik3cd*^{E1020K/+} (CD45.2⁺) bone marrow cells, transferred into irradiated wild-type hosts (CD45.1/2⁺). **j**, Frequency of B220⁺CD19⁺GL-7⁺FAS⁺ GC B cells within wild-type and *Pik3cd*^{E1020K/+} cells, and live GC B cells (Annexin⁻ viability dye⁻). **k**, FO B cells were kept *in vitro* without stimulation and analyzed for viability at different time points (wild-type open circles, mutant closed circles). **l**, **m**, FO B cells were activated *in vitro* for 3 days with the indicated stimuli and assessed for CTV dilution and viability. **n**, FO B cells were stimulated *in vitro* with LPS+IL-4, treated with or without CAL-101 (PI3K δ inhibitor) and analyzed for CTV dilution and viability on day+3 (**k-n**, pool of 2-3 mice per group). Data are representative of 2 (**a**, **b-g**, **i-k**, **n**), and 3 (**h**, **l**, **m**) independent experiments. Data are expressed as mean $\pm$ SEM with each dot indicating one mouse. Significance analyzed by Mann-Whitney U test. ***P* < 0.01.



Supplementary Figure 6
<i>Pik3cd</i> ^{E1020K/+} mice develop IgM autoantibodies.
(a-b) Wild-type and <i>Pik3cd</i>^{E1020K/+} sera were analyzed at 14-16 weeks of age. a, ELISA for serum ANA-IgM (n=5 per group). b, Serum IgM autoantibody array chip is shown; a colorimetric representation of relative autoantibody reactivity in each sample and for each self-antigen is shown based on the scale (0-3) depicted on top of the heat map. The sera of 3 wild-type and 11 <i>Pik3cd</i>^{E1020K/+} were analyzed, and sera from 2 lupus-prone MRL/NZM mice were used as a positive control. Data in (a) are representative of 2 independent experiments. Data in (b) have been obtained from one experiment examining sera from multiple litters. Data are expressed as mean $\pm$ SEM with each dot indicating one mouse. Significance analyzed by Mann-Whitney U test. *<i>P</i> < 0.05.



Supplementary Figure 7

Disorganized GCs in *Pik3cd*^{E1020K/+} mLN, and microbiome composition of wild-type and *Pik3cd*^{E1020K/+} mice.

a. Confocal immunofluorescence images from the mLNs of naïve wild-type and *Pik3cd*^{E1020K/+} mice (scale bar 200 μ m left panel; 30 μ m

enlargements). White dotted line denotes the boundary between the B cell follicle and T cell zone and is based on B220 staining (not shown). CD35 staining intensity was used to mark the light zones (LZ) and dark zones (DZ) of the GC (BCL-6⁺). Images are representative of mLN from 2 mice per group from 2 separate experiments. **b**, Numbers of GCs per mLN (n=1 per group). **c**, Histograms were used to quantify the distribution of T_{FH} cells in DZ as described in Supplementary Figure 3f. The percentage of cells within the DZ gate is shown. Each symbol refers to a GC. **d**, Normalized numbers of T_{FH} cells (identified as in **c**) per DZ GC area (BCL-6⁺ CD35⁻) (**c**, **d**, wild-type n=9, *Pik3cd*^{E1020K/+} n=19) **e**, Bar plots of baseline microbiota profile by 16s rRNA sequencing in wild-type (n=8) and *Pik3cd*^{E1020K/+} (n=6). Relative family-level abundances of fecal samples prior to sorting based on IgA are shown. **f**, Principal Coordinates Analysis (PCoA) plot shown using the Canberra beta diversity metric, performed on baseline microbiota profiles (wild-type n=8; *Pik3cd*^{E1020K/+}, n=6). Significance of clustering based on genotype (wild-type vs. *Pik3cd*^{E1020K/+} mice) was assessed using PERMANOVA (P=0.46). Data in (**e**, **f**) have been obtained from 3 independent experiments. Shown is the mean ± SEM. Differences between groups were compared with Mann-Whitney *U* test. **P* < 0.05.